TNF/TNFR: Drug target for autoimmune diseases and immune-mediated inflammatory diseases

Frontiers in Bioscience - Landmark

Volumn 19, Issue 7, 2014, Pages 1028-1040

  Doss C, George Priya ^a   Agoramoorthy, Govindasamy ^b   Chakraborty, Chiranjib ^c  

^a VIT UNIVERSITY   (India)

^b TAJEN UNIVERSITY   (Taiwan)

^c GALGOTIAS UNIVERSITY   (India)

Author keywords

IMIDs; Immune mediated inflammatory diseases; Review; Small molecule inhibitors; TNF receptor 1; TNF receptor 2; TNF beta; ; TNF ; TNFR1; TNFR2

Indexed keywords

TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2;

ANTAGONISTS AND INHIBITORS; AUTOIMMUNE DISEASES; DRUG EFFECTS; HUMAN; INFLAMMATION; METABOLISM; MOLECULARLY TARGETED THERAPY; PROCEDURES; SIGNAL TRANSDUCTION;

AUTOIMMUNE DISEASES; HUMANS; INFLAMMATION; MOLECULAR TARGETED THERAPY; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84904654888     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/4265     Document Type: Article

References (164)

1. Carswell, E. A., Old, L. J., Kassel, R. L., Green, S., Fiore, N., Williamson, B: An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A. 72(9): 3666-70 (1975).
2. Wiemann, B., and Starnes, C. O: Coley's toxins, tumor necrosis factor and cancer research: a historical perspective. Pharmacol Ther 64: 529-564 (1994). (Pubitemid 24381235)
3. Kawakami, M., and Cerami, A. Studies of endotoxininduced decrease in lipoprotein lipase activity. J Exp Med 154: 631-639 (1981). (Pubitemid 11060776)
4. Beutler, B., Mahoney, J., Le Trang, N., Pekala, P., and Cerami, A: Purification of cachectin, a lipoprotein lipase-suppressing hormone secreted by endotoxininduced RAW 264.7 cells. J Exp Med 161: 984-995 (1985). (Pubitemid 15011320)
5. Beutler, B., Greenwald, D., Hulmes, J. D., Chang, M., Pan, Y. C., Mathison, J., Ulevitch, R., Cerami, A: Identity of tumour necrosis factor and the macrophagesecreted factor cachectin. Nature 316: 552-554 (1985). (Pubitemid 16239366)
6. Pennica, D., Hayflick, J. S., Bringman, T. S., Palladino, M. A., and Goeddel, D. V: Cloning and expression in Escherichia coli of the cDNA for murine tumor necrosis factor. Proc Natl Acad Sci USA 82: 6060-6064 (1985). (Pubitemid 16223898)
7. Croft, M:. The role of TNF superfamily members in T-cell function and diseases. Nature Rev. Immunol. 9: 271-285 (2009).
8. Ousman, S. S., and David, S: MIP-1alpha;, MCP-1, GM-CSF, and TNF-α control the immune cell response that mediates rapid phagocytosis of myelin from the adult mouse spinal cord. The Journal of Neuroscience 21: 4649-4656 (2001). (Pubitemid 32565623)
9. Scott, K. A., Arnott, C. H., Robinson, S. C., Moore, R. J., Thompson, R. G., Marshall, J. F., Balkwill, F. R: TNF-α regulates epithelial expression of MMP-9 and integrin avβ6 during tumour promotion. A role for TNF-α in keratinocyte migration? Oncogene 23: 6954-6966 (2004).
10. Ferreira, S. H., Lorenzetti, B. B., Cunha, F. Q., Poole, S: Bradykinin release of TNF-α plays a key role in the development of inflammatory hyperalgesia. Agents Actions. 38: C7-C9 (1993). (Pubitemid 23117973)
11. Micheau, O., and Tschopp, J: Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. Cell 114(2): 181-90 (2003). (Pubitemid 36936912)
12. Aggarwal, B. B: Signalling pathways of the TNF superfamily: a double-edged sword. Nature Reviews Immunology 3(9): 745-756 (2003). (Pubitemid 41070815)
13. Wortzman, M. E., Lin, G. H., Watts, T. H: Intrinsic TNF/TNFR2 interactions fine-tune the CD8 T cell response to respiratory influenza virus infection in mice. PLoS One 8(7): e68911 (2013).
14. Hsu, H., Huang, J., Shu, H. B., Baichwal, V., Goeddel, D. V: TNF-dependent recruitment of the protein kinase RIP to the TNF receptor-1 signaling complex. Immunity 4: 387-396 (1996). (Pubitemid 26174054)
15. Palanki, M. S., Erdman, P. E., Gayo-Fung, L. M., Shevlin, G. I., Sullivan, R. W., Suto, M. J., Goldman, M. E., Ransone, L. J., Bennett, B. L., Manning, A.M: Inhibitors of NF-kappaB and AP-1 gene expression:SAR studies on the pyrimidine portion of N-(3,5- bis(trifluoromethyl)phenyl)(2-chloro-4- (trifluoromethyl)pyrimidin-5-yl)carboxamide; NF-kappa B; Pyrimidines; Transcription Factor AP-1. J Med Chem 43: 3995-4004 (2000).
16. Sudhakar, C., Nagabhushana, A., Jain, N., Swarup, G: NF-κB Mediates Tumor Necrosis Factor a-Induced Expression of Optineurin, a Negative Regulator of NF-κB PLoS One 4(4): e5114 (2009).
17. Stefan ova I., Dorfman J. R. and Germain R. N: Selfrecognition promotes the foreign antigen sensitivity of naive T lymphocytes". Nature 420 (6914): 429-434 (2002). (Pubitemid 35415655)
18. American Autoimmune Related Diseases Association (http://www.aarda.org).
19. Anonymous. Autoimmune disease. Nat Biotechnol. 18 Suppl: IT7-9 (2000).
20. Breedveld, F. C., Weisman, M. H., Kavanaugh, A. F., Cohen, S. B., Pavelka, K., van Vollenhoven, R., Sharp, J., Perez, J. L., Spencer-Green, G. T: The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 54: 26-37 (2006). (Pubitemid 43122183)
21. Klaresko,g L., van der Heijde, D., de Jager, J. P., Gough, A., Kalden, J., Malaise, M., Martín Mola, E., Pavelka, K., Sany, J., Settas, L., Wajdula, J., Pedersen, R., Fatenejad, S., Sanda, M., TEMPO (Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes) study investigators: Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomized controlled trial. Lancet 363, 675-681 (2004). (Pubitemid 38296553)
22. Amor, S., Puentes, F., Baker, D., van der Valk P: Inflammation in neurodegenerative diseases. Immunology 129(2):154-69 (2010).
23. Yanai, H., Shuster, D., Calabrese, E., Mlynarsky, L., Tumuluri, S., Cohen, R. D: The incidence and predictors of lupus-like reaction in patients with IBD treated with antitnf therapies. Inflamm Bowel Dis. 19(13): 2778-86 (2013).
24. Williams, J. P., and Meyers, J. A: Immune-mediated inflammatory disorders (I.M.I.D.s): the economic and clinical costs. Am J Manag Care 8(21 Suppl): S664-S681. (2002). (Pubitemid 36050139)
25. Beyaert, R., Beaugerie, L., Van Assche, G., Brochez, L., Renauld, J. C., Viguier, M., Cocquyt, V., Jerusalem, G., Machiels, J. P., Prenen, H., Masson, P., Louis, E., De Keyser, F:s Cancer risk in immune-mediated inflammatory diseases (IMID). Mol Cancer 12(1): 98 (2013).
26. Chu, W. M: Tumor necrosis factor. Cancer Lett 328(2): 222-5 (2013).
27. Croft, M., Duan, W., Choi, H., Eun, S. Y., Madireddi, S., Mehta, A: TNF superfamily in inflammatory disease: translating basic insights. Trends Immunol 33(3): 144-52 (2012).
28. Vinay, D. S., and Kwon, B. S: The tumour necrosis factor/TNF receptor superfamily: therapeutic targets in autoimmune diseases. Clin Exp Immunol. 164(2): 145-57 (2011).
29. Vinay, D. S., and Kwon, B. S: Genes, transcripts, and proteins of CD137 receptor and ligand. In: ChenL, ed. CD137 pathway: immunology and diseases. New York: Springer, 1-14 (2006).
30. Croft, M: The role of TNF superfamily members in T-cell function and diseases. Nat Rev Immunol 9: 271-85 (2009).
31. Vinay, D. S., and Kwon, B. S. TNF superfamily: costimulation and clinical applications. Cell Biol Int 33: 453-65 (2009).
32. Aggarwal, B. B., Gupta, S. C., and Kim, J. H: Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey. Blood 119(3): 651-665 (2012).
33. Sharma, O. P: Tumor necrosis factor polymorphism in sarcoidosis. Chest 119: 678-679 (2001). (Pubitemid 32197630)
34. Parham, P: T cell-mediated immunity. The immune system, 2nd ed. New York: Garland Science Publishing,145-178 (2005).
35. Seifart, C., Dempfle, A., Plagens, A., Seifart, U., Clostermann, U., Müller, B., Vogelmeier, C., von Wichert, P: TNF-α-, TNF-beta-, IL-6-, and IL-10-promoter polymorphisms in patients with chronic obstructive pulmonary disease. Tissue Antigens 65(1) 93-100 (2005). (Pubitemid 40179668)
36. Goyal, A., Kazim, S. N., Sakhuja, P., Malhotra, V., Arora, N., Sarin, S. K: Association of TNF-beta polymorphism with disease severity among patients infected with hepatitis C virus. J Med Virol 72: 60-5 (2004). (Pubitemid 37484744)
37. Koch, W., Kastrati, A., Böttiger, C., Mehilli, J., von Beckerath, N., Schömig, A: Interleukin-10 and tumor necrosis factor gene polymorphisms and risk of coronary artery disease and myocardial infarction. Atherosclerosis 159: 137-44 (2001). (Pubitemid 33016630)
38. Mas, A., Blanco, E., Moñux, G., Urcelay, E., Serrano, F. J., de la Concha, E. G., Martínez, A: DRB1-TNF-α-TNF-beta haplotype is strongly associated with severe aortoiliac occlusive disease, a clinical form of atherosclerosis. Hum Immunol 66: 1062-7 (2005). (Pubitemid 43005009)
39. Badenhoop, K., Schwarz, G., Schleusener, H., Weetman, A. P., Recks, S., Peters, H., Bottazzo, G. F., Usadel, K. H: Tumor necrosis factor beta gene polymorphisms in Graves' disease. J Clin Endocrinol Metab 74: 287-91 (1992).
40. Kuntz, I. D: Structure-based strategies for drug design and discovery. Science 257: 1078-82 (1992).
41. Scapin, G: Structural biology in drug design: selective protein kinase inhibitors. Drug Discov Today 7: 601-11 (2002). (Pubitemid 34603627)
42. Baud, V., and Karin, M: Signal transduction by tumor necrosis factor and its relatives. Trends in cell biology 11(9): 372-377 (2001). (Pubitemid 32900529)
43. Vielhauer, V., and Mayadas, T. N: Functions of TNF and its receptors in renal disease: distinct roles in inflammatory tissue injury and immune regulation. Semin nephrology 27(3): 286-308 (2007). (Pubitemid 46802916)
44. Aggarwal, B. B: Signalling pathways of the TNF superfamily: a double-edged sword. Nature Rev. Immunol. 3: 745-756 (2003). (Pubitemid 41070815)
45. Wicovsky, A., Henkler, F., Salzmann, S., Scheurich, P., Kneitz, C., and Wajant, H: Tumor necrosis factor receptorassociated factor-1 enhances proinflammatory TNF receptor-2 signaling and modifies TNFR1-TNFR2 cooperation. Oncogene, 28(15): 1769-1781 (2009).
46. Mak TW, Saunders ME: The immune response : basic and clinical principles. New York: Elsevier/Academic; 2011.
47. Germain, R. N: An innately interesting decade of research in immunology. Nature medicine, 10(12): 1307-1320 (2004). (Pubitemid 40022712)
48. Trudeau, J. D., Kelly-Smith, C., Verchere, C. B., Elliott, J. F., Dutz, J. P., Finegood, D. T., and Tan, R: Prediction of spontaneous autoimmune diabetes in NOD mice by quantification of autoreactive T cells in peripheral blood. Journal of Clinical Investigation, 111(2): 217-223 (2003). (Pubitemid 36105920)
49. Cupedo, T., Nagasawa, M., Weijer, K., Blom, B., & Spits, H. Development and activation of regulatory T cells in the human fetus. European journal of immunology 35(2): 383-390 (2005). (Pubitemid 40331315)
50. Cupedo, T., Nagasawa, M., Weijer, K., Blom, B., & Spits, H. Development and activation of regulatory T cells in the human fetus. European journal of immunology 35(2): 383-390 (2005) 50.Rosmalen, J. G., van Ewijk, W., Leenen, P. J: T-cell education in autoimmune diabetes: teachers and students. Trends Immunol 23(1): 40-6 (2002). (Pubitemid 34098960)
51. Faustman, D. L., and Davis, M. The primacy of CD8 T lymphocytes in type 1 diabetes and implications for therapies. J. Mol. Med. 87: 1173-1178 (2009).
52. Zuniga-Pflucker, J. C., Di, J., and Lenardo, M. J. Requirement for TNF-α and IL-1 alpha; in fetal thymocyte commitment and differentiation. Science 268: 1906-1909 (1995).
53. Samira, S., Ferrand, C., Peled, A., Nagler, A., Tovbin, Y., Ben-Hur, H., Taylor, N., Globerson, A., Lapidot, T: Tumor necrosis factor promotes human T-cell development in nonobese diabetic/severe combined immunodeficient mice. Stem Cells 22: 1085-1100 (2004). (Pubitemid 39507094)
54. Brignier, A. C., Gewirtz, A. M: Embryonic and adult stem cell therapy. Journal of Allergy and Clinical Immunology, 125(2): S336-S344. (2010).
55. Kollias, G., and Kontoyiannis, D: Role of TNF/TNFR in autoimmunity: specific TNF receptor blockade may be advantageous to anti-TNF treatments. Cytokine Growth Factor Rev 13(4-5): 315-21 (2002).
56. Kodama, S., Davis, M., Faustman, D. L: The therapeutic potential of tumor necrosis factor for autoimmune disease: a mechanistically based hypothesis. Cell Mol Life Sci. 62(16): 1850-62 (2005). (Pubitemid 41188524)
57. Hayashi, T., and Faustman D: NOD mice are defective in proteasome production and activation of NF-kappaB. Mol. Cell. Biol. 19: 8646-8659 (1999). (Pubitemid 30414057)
58. Kim, S., Millet, I., Kim, H. S., Kim, J. Y., Han, M. S., Lee, M. K., Kim, K. W., Sherwin, R. S., Karin, M., Lee, M. S: NF-kappa B prevents beta cell death and autoimmune diabetes in NOD mice. Proc Natl Acad Sci U S A. 104(6): 1913-8 (2007). (Pubitemid 46239878)
59. Jacob, C. O. Tumor necrosis factor a in autoimmunity: pretty girl or old witch?. Immunology today, 13(4): 122-125 (1992).
60. Lenardo, M. J: Interleukin-2 programs mouse alpha; beta T lymphocytes for apoptosis. Nature 353, 858-861 (1991). (Pubitemid 21912642)
61. Mikuls, T. R., Moreland, L. W: TNF blockade in the treatment of rheumatoid arthritis: infliximab versus etanercept. Exp. Opin. Pharmacother 2: 75 (2001).
62. Blam, M. E.; Stein, R. B.; Lichtenstein, G. R: Integrating anti-tumor necrosis factor therapy in inflammatory bowel disease: current and future perspectives. Am. J. Gastroenterol 96, 1977-97 (2001). (Pubitemid 32660888)
63. Palladino, M. A., Bahjat, F. R., Emmanuel, A., Theodorakis, E. A., Moldawer, L. L: Nature Rev. Drug Discov 2: 736 (2003).
64. Cheng, J.-F., Ishikawa, A., Ono, Y., Arrhenius, T., Nadzan, A: Novel chromene derivatives as TNF-α inhibitors. Bioorg. Med. Chem. Lett. 13(21): 3647-3650 (2003). (Pubitemid 37206478)
65. Cheng, J. F., Chen, M., Wallace, D., Tith, S., Arrhenius, T., Kashiwagi, H., Ono, Y., Ishikawa, A., Sato, H., Kozono, T., Sato, H., Nadzan, A.M: Discovery and structure-activity relationship of coumarin derivatives as TNF-α inhibitors. Bioorg. Med. Chem. Lett. 14: 2411-2415 (2004). (Pubitemid 38515676)
66. Beyaert, R., and Fiers, W: Molecular mechanisms of tumor necrosis factor-induced cytotoxicity. What we do understand and what we do not. FEBS Lett 340: 9-16 (1994).
67. Beyaert, R., and Fiers, W: Molecular mechanisms of tumor necrosis factor-induced cytotoxicity. What we do understand and what we do not. FEBS Lett 340: 9-16 (1994) 67.Watts, A. D., Hunt, N. H., Hambly, B. D., Chaudhri, G: Separation of tumor necrosis factor alpha; isoforms by twodimensional polyacrylamide gel electrophoresis. Electrophoresis 18: 1086-1091 (1997). (Pubitemid 27285848)
68. Vilcek, J., and Lee, T. H: Tumor necrosis factor. New insights into the molecular mechanisms of its multiple actions. J Biol Chem 266: 7313-7316 (1991). (Pubitemid 21906368)
69. Kriegler, M., Perez, C., DeFay, K., Albert, I., Lu, S. D: A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane protein: ramifications for the complex physiology of TNF. Cell 53: 45-53 (1988).
70. Smith, R. A., and Baglioni, C. The active form of tumor necrosis factor is a trimer. J Biol Chem 262: 6951-6954 (1987). (Pubitemid 17105009)
71. Banner, D. W., D'Arcy, A., Janes, W., Gentz, R., Schoenfeld, H. J., Broger, C., Loetscher, H., Lesslauer, W: Crystal structure of the soluble human 55 kd TNF receptor-human TNF beta complex: implications for TNF receptor activation. Cell 73:431-445 (1993). (Pubitemid 23143344)
72. Browning, J. L., Ngam-ek, A., Lawton, P., DeMarinis, J., Tizard, R., Chow, E. P., Hession, C., O'Brine-Greco, B., Foley, S. F., Ware, C.F: Lymphotoxin beta, a novel member of the TNF family that forms a heteromeric complex with lymphotoxin on the cell surface. Cell 72: 847-56 (1993). (Pubitemid 23110227)
73. Eck, M. J., Sprang, S. R: The structure of tumor necrosis factor alpha; at 2.6 A resolution. Implications for receptor binding. J Biol Chem 264: 17595-17605 (1989). (Pubitemid 19255596)
74. Reed, C., Fu, Z. Q., Wu, J., Xue, Y. N., Harrison, R. W., Chen, M. J., Weber, I. T: Crystal structure of TNF-α mutant R31D with greater affinity for receptor R1 compared with R2. Protein Eng 10: 1101-1107 (1997). (Pubitemid 28046171)
75. Vilcek, J., and Lee, T. H: Tumor necrosis factor. New insights into the molecular mechanisms of its multiple actions. J Biol Chem 266: 7313-7316 (1991). (Pubitemid 21906368)
76. Fiers, W: Tumor necrosis factor. Characterization at the molecular,cellular and in vivo level. FEBS Lett 285:199-212 (1991).
77. Banner, D. W., D'Arcy, A., Janes, W., Gentz, R., Schoenfeld, H. J., Broger, C., Loetscher, H., Lesslauer, W: Crystal structure of the soluble human 55 kd TNF receptorhuman TNF beta complex: implicationsfor TNF receptor activation. Cell 73: 431-445 (1993). (Pubitemid 23143344)
78. Croft, M: The role of TNF superfamily members in T-cell function and diseases. Nature Rev Immunol 9: 271-285 (2009).
79. Aggarwal, B., Vilcek, J: Eds.. Tumor necrosis factors: structure, function and mechanism. Marcel Dekker Publishers, New York. 1991.
80. Vilcek, J., and Lee, T. H: Tumor necrosis factor. New insights into the molecular mechanisms of its multiple actions. J Biol Chem 266:7313-7316 (1991). (Pubitemid 21906368)
81. Krueger, J. M., Obál, F. J., Fang, J., Kubota, T., Taishi, P: The role of cytokines in physiological sleep regulation. Ann N Y Acad Sci 933: 211-21 (2001). (Pubitemid 32386036)
82. Kapsimalis, F., Richardson, G., Opp, M. R., Kryger, M: Cytokines and normal sleep. Curr Opin Pulm Med 11: 481-4 (2005). (Pubitemid 41564996)
83. Inancli, H. M., and Enoz, M: Obstructive sleep apnea syndrome and upper airway inflammation. Recent Pat Inflamm Allergy Drug Discov 4: 54-7 (2010).
84. Wride, M. A., and Sanders, E. J: Potential roles for tumour necrosis factor alpha; during embryonic development. Anat Embryol (Berl) 191:1-10 (1995).
85. Arsenescu, R., Arsenescu, V., de Villiers, W. J: TNF-α and the development of the neonatal immune system: implications for inhibitor use in pregnancy. Am J Gastroenterol 106: 559-62 (2011).
86. Shoham, S., Davenne, D., Cady, A. B., Dinarello, C. A., Krueger, J. M: Recombinant tumor necrosis factor and interleukin 1 enhance slow wave sleep. Am J Physiol 253: R142-149 (1987).
87. Everson, C. A: Functional consequences of sustained sleep deprivation in the rat. Behav Brain Res 69: 43-54 (1995).
88. Krueger, J. M., Fang, J., Taishi, P., Chen, Z., Kushikata, T., Gardi, J: Sleep. A physiologic role for IL-1 beta and TNF-α. Ann N Y Acad Sci 856: 148-59 (1998). (Pubitemid 128713055)
89. Brill, A., Torchinsky, A., Carp, H., and Toder, V: The role of apoptosis in normal and abnormal embryonic development. J Assist Reprod Genet 16: 512-9 (1999). (Pubitemid 29529928)
90. Wride, M. A., and Sanders, E. J. Potential roles for tumour necrosis factor alpha; during embryonic development. Anat Embryol (Berl) 191: 1-10 (1995).
91. Caminero, A., Comabella, M., Montalban, X: Tumor necrosis factor alpha; (TNF-α), anti-TNF-α and demyelination revisited: an ongoing story. J Neuroimmunol 234(1-2): 1-6 (2011).
92. Idriss, H. T., Naismith, J. H: TNF alpha; and the TNF receptor superfamily: structure-function relationship(s). Microsc Res Tech 50(3):184-95 (2000). (Pubitemid 30610095)
93. Naismith, J. H., Devine, T. Q., Kohno, T., Sprang, S. R: Structures of the extracellular domain of the type I tumor necrosis factor receptor. Structure 4: 1251-1262 (1996). (Pubitemid 26420495)
94. Bazzoni, F., and Beutler, B: The tumor necrosis factor ligand and receptor families. N Engl J Med 334: 1717-1725 (1996). (Pubitemid 26193625)
95. Beyaert, R., and Fiers, W: Molecular mechanisms of tumor necrosis factor-induced cytotoxicity. What we do understand and what we do not. FEBS Lett 340: 9-16 (1994).
96. Fiers, W: Tumor necrosis factor. Characterization at the molecular, cellular and in vivo level. FEBS Lett 285: 199-212 (1991).
97. Gaeta, M. L., Johnson, D. R., Kluger, M. S., Pober, J. S: The death domain of tumor necrosis factor receptor 1 is necessary but not sufficient for Golgi retention of the receptor and mediates receptor desensitization. Lab Invest 80:1185-94 (2000). (Pubitemid 30637058)
98. Tartaglia, L. A., Ayres, T. M., Wong, G. H., Goeddel, D. V: A novel domain within the 55 kd TNF receptor signals cell death. Cell 74: 845-853 (1993). (Pubitemid 23270604)
99. Hsu, H., Xiong, J., Goeddel, D. V: The TNF receptor 1- associated protein TRADD signals cell death and NF-ΚB activation. Cell 81: 495-504 (1995).
100. Josephs, M. D., Bahjat, F. R., Fukuzuka, K., Ksontini, R., Solorzano, C. C., Edwards, C. K. 3rd, Moldawer L. L: Lipopolysaccharide and D-galactosamine-induced hepatic injury is mediated by TNF-α and not by Fas ligand. Am J Physiol Regul Integr Comp Physiol 278: R1196-R1201 (2000). (Pubitemid 30366447)
101. Evans, T. J., Moyes, D., Carpenter, A., Martin, R., Loetscher, H., Lesslauer, W., Cohen, J: Protective effect of 55- but not 75-kD soluble tumor necrosis factor receptor- immunoglobulin G fusion proteins in an animal model of gram-negative sepsis. J Exp Med 180, 2173-2179 (1994). (Pubitemid 24351598)
102. Mukai, Y., Nakamura, T., Yoshikawa, M., Yoshioka, Y., Tsunoda, S., Nakagawa, S: Crystallization and preliminary Xray analysis of the tumour necrosis factor alpha;-tumour necrosis factor receptor type 2 complex. Acta Crystallogr Sect F Struct Biol Cryst Commun 65: 295-298 (2009).
103. Mukai, Y., Shibata, H., Nakamura, T., Yoshioka, Y., Abe, Y., Nomura, T., Taniai, M., Ohta, T., Ikemizu, S: Structure- function relationship of tumor necrosis factor (TNF) and its receptor interaction based on 3D structural analysis of a fully active TNFR1-selective TNF mutant. J Mol Biol 385: 1221-1229 (2009).
104. Pimentel-Muinos, F. X., and Seed, B: Regulated commitment of TNF receptor signaling: a molecular switch for death or activation. Immunity 11: 783-793 (1999). (Pubitemid 30030717)
105. Kodama, S., Davis, M., and Faustman, D. L: The therapeutic potential of tumor necrosis factor for autoimmune disease: a mechanistically based hypothesis. Cell Mol Life Sci. 62: 1850-1862 (2005). (Pubitemid 41188524)
106. Faustman, D., Li, X. P., Lin, H. Y., Fu, Y. E., Eisenbarth, G., Avruch, J., Guo, J: Linkage of faulty major histocompatibility complex class I to autoimmune diabetes. Science 254: 1756-1761 (1991). (Pubitemid 21917518)
107. Faustman, D. L., and Davis, M. The primacy of CD8 T lymphocytes in type 1 diabetes and implications for therapies. J. Mol. Med. 87: 1173-1178 (2009).
108. Matsumura, R., Umemiya, K., Kagami, M., Tomioka, H., Tanabe, E., Sugiyama, T., Sueishi, M,, Kayagaki, N., Yagita, H., Okumura, K: Expression of TNF-related apoptosis inducing ligand (TRAIL) on infiltrating cells and of TRAIL receptors on salivary glands in patients with Sjögren's syndrome. Clin Exp Rheumatol.20: 791-8 (2002). (Pubitemid 35446969)
109. Abbott, D. W., Wilkins, A., Asara, J. M., Cantley, L. C: The Crohn's disease protein, NOD2, requires RIP2 in order to induce ubiquitinylation of a novel site on NEMO. Curr. Biol. 14: 2217-2227 (2004). (Pubitemid 40033358)
110. Eckmann, L., and Karin, M: NOD2 and Crohn's disease: loss or gain of function? Immunity 22, 661-667 (2005). (Pubitemid 40814497)
111. Akassoglou, K., Bauer, J., Kassiotis, G., Pasparakis, M., Lassmann, H., Kollias, G., Probert, L: Oligodendrocyte apoptosis and primary demyelination induced by local TNF/p55TNF receptor signaling in the central nervous system of transgenic mice: models for multiple sclerosis with primary oligodendrogliopathy. Am J Pathol 153: 801-13 (1998). (Pubitemid 28419033)
112. Kollias, G., Douni, E., Kassiotis, G., Kontoyiannis, D: On the role of tumor necrosis factor and receptors in models of multiorgan failure, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease. Immunol Rev 169:175-94 (1999). (Pubitemid 29338732)
113. Svenungsson, E., Fei, G. Z., Jensen-Urstad, K., de Faire, U., Hamsten, A., Frostegard, J: TNF-α: a link between hypertriglyceridaemia and inflammation in SLE patients with cardiovascular disease. Lupus 12: 454-61 (2003). (Pubitemid 36830119)
114. Crew, M. D., Effros, R. B., Walford, R. L., Zeller, E., Cheroutre H, Brahn E. Transgenic mice expressing a truncated Peromyscus leucopus TNF-α gene manifest an arthritis resembling ankylosing spondylitis. J Interferon Cytokine Res. 18: 219-25 (1998). (Pubitemid 28176004)
115. Grewal, I. S., Grewal, K. D., Wong, F. S., Picarella, D. E., Janeway, C. A., Jr, Flavell R. A: Local expression of transgene encoded TNF alpha; in islets prevents autoimmune diabetes in non-obese diabetic (NOD) mice by preventing the development of autoreactive islet specific T cells. J. Exp. Med. 184: 1963-1974 (1996). (Pubitemid 26404486)
116. Ryu, S., Kodama, S., Ryu, K., Schoenfeld, D. A., Faustman, D. L: Reversal of established autoimmune diabetes by restoration of endogenous beta cell function. J. Clin Invest 108: 63-72 2001. (Pubitemid 32634923)
117. Nishio, J., Gaglia, J. L., Turvey, S. E., Campbell, C., Benoist, C., Mathis, D: Islet recovery and reversal of murine type 1 diabetes in the absence of any infused spleen cell contribution. Science 311: 1775-1778 (2006).
118. Chong, A. S., Shen, J., Tao, J., Yin, D., Kuznetsov, A., Hara, M., Philipson, L. H: Reversal of diabetes in non obese diabetic mice without spleen cell-derived beta cell regeneration. Science 311: 1774-1775 (2006).
119. Ban, L., Zhang, J., Wang, L., Kuhtreiber, W., Burger, D., Faustman, D. L: Selective death of autoreactive T cells in human diabetes by TNF or TNF receptor 2 agonism. Proc. Natl Acad. Sci. USA 105: 13644-13649 (2008).
120. Faustman, D., and Davis, M: TNF receptor 2 pathway: drug target for autoimmune diseases. Nat Rev Drug Discov 9: 482-93 (2010).
121. Shmidt, E., Wetter, D. A., Ferguson, S. B., Pittelkow, M. R: Psoriasis and palmoplantar pustulosis associated with tumor necrosis factor-a inhibitors: The Mayo Clinic experience, 1998 to 2010. J Am Acad Dermatol. 67(5):e179-85 (2011).
122. Rémy, A., Avouac, J., Gossec, L., Combe, B: Clinical relevance of switching to a second tumour necrosis factoralpha; inhibitor after discontinuation of a first tumour necrosis factor-alpha; inhibitor in rheumatoid arthritis: a systematic literature review and meta-analysis. Clin Exp Rheumatol. 29: 96-103 (2011).
123. Shenoi, S., and Wallace, C. A: Tumor necrosis factor inhibitors in the management of juvenile idiopathic arthritis: an evidence-based review. Paediatr Drugs 12: 367-77 (2010).
124. Yende, S., van der Poll, T., Lee, M., Huang, D. T., Newman, A. B., Kong, L., Kellum, J. A., Harris, T. B., Bauer, D., Satterfield, S., Angus, D. C: The influence of pre-existing diabetes mellitus on the host immune response and outcome of pneumonia: analysis of two multicentre cohort studies. Thorax 65: 870-7 (2010).
125. Kodama, S., Kuhtreiber, W., Fujimura, S., Dale, E. A., Faustman, D. L: Islet regeneration during the reversal of autoimmune diabetes in NOD mice. Science 302:1223-1227 (2003). (Pubitemid 37421029)
126. Comi, C., Leone, M., Bonissoni, S., DeFranco, S., Bottarel, F., Mezzatesta, C., Chiocchetti, A., Perla, F., Monaco, F., Dianzani, U: Defective T cell fas function in patients with multiple sclerosis. Neurology 55: 921-7 (2000).
127. Monden, Y., Kubota, T., Inoue, T., Tsutsumi, T., Kawano, S., Ide, T., Tsutsui, H., Sunagawa, K: Tumor necrosis factor-alpha; is toxic via receptor 1 and protective via receptor 2 in a murine model of myocardial infarction. Am. J. Physiol. Heart Circ. Physiol 293: H743-H753 (2007). (Pubitemid 47105137)
128. Campbell, J., Ciesielski, C. J., Hunt, A. E., Horwood, N. J., Beech, J. T., Hayes, L. A., Denys, A., Feldmann, M., Brennan, F. M., Foxwell, B. M: A novel mechanism for TNF-α regulation by p38 MAPK: involvement of NFkappa B with implications for therapy in rheumatoid arthritis. J Immunol 173: 6928-37 (2004). (Pubitemid 39541081)
129. Gottlieb, A. B., Chamian, F., Masud, S., Cardinale, I., Abello, M. V., Lowes, M. A., Chen, F., Magliocco, M., Krueger, J. G: TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques. J Immunol.175: 2721-9 (2005). (Pubitemid 41113889)
130. Dieude, P., Petit, E., Cailleau-Moindrault, S., Osorio, J., Pierlot, C., Martinez, M., Fauré, S., Alibert, O., Lasbleiz, S., De Toma, C., Bardin, T., Prum, B., Cornélis, F: Association between tumor necrosis factor receptor II and familial, but not sporadic, rheumatoid arthritis: evidence for genetic heterogeneity. Arthritis Rheum 46: 2039-2044 (2002).
131. Pierik, M., Vermeire, S., Steen, K. V., Joossens, S., Claessens, G., Vlietinck, R., Rutgeerts, P: Tumour necrosis factor-a receptor 1 and 2 polymorphisms in inflammatory bowel disease and their association with response to infliximab. Aliment Pharmacol Ther 20: 303-310 (2004). (Pubitemid 39062133)
132. Zhu, L. J., Landolt-Marticorena, C., Li, T., Yang, X., Yu, X. Q., Gladman, D. D., Urowitz, M. B., Fortin, P. R., Wither, J. E: Altered expression of TNF-α signaling pathway proteins in systemic lupus erythematosus. J Rheumatol 37:1658-66 (2010).
133. Sousa, E., Caetano-Lopes, J., Pinto, P., Pimentel, F., Teles, J., Canhão, H., Rodrigues, A., Resende, C., Mourão, A. F., Ribeiro, C., Pinto, T. L., Rosa, C. M., da Silva, J. A., Branco, J., Ventura, F., Queiroz, M. V., Fonseca, J.E: Ankylosing spondylitis susceptibility and severity-contribution of TNF gene promoter polymorphisms at positions -238 and -308. Ann N Y Acad Sci.1173: 581-8 (2009).
134. Majetschak, M., Flohé, S., Obertacke, U., Schröder, J., Staubach, K., Nast-Kolb, D., Schade, F. U., Stüber, F: Relation of a TNF gene polymorphism to severe sepsis in trauma patients. Ann Surg 230: 207-14 (1999). (Pubitemid 30191887)
135. Brekke, O. H., and Sandlie, I: Therapeutic antibodies for human diseases at the dawn of the twentyfirst century. Nat Rev Drug Discov 2: 52-62 (2003). (Pubitemid 37361624)
136. Kempeni, J: Preliminary results of early clinical trials with the fully human anti-TNFa monoclonal antibody D2E7. Ann Rheum Dis 58: I70 (1999).
137. Mazumdar, S., Greenwald, D: Golimumab. MAbs 1: 422-431 (2009).
138. Kay, J., Matteson, E. L., Dasgupta, B., Nash, P., Durez, P., Hall, S., Hsia, E. C., Han, J., Wagner, C., Xu, Z., Visvanathan, S., Rahman, M. U: Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double blind, placebo-controlled, dose-ranging study. Arthritis Rheum 58: 964-75 (2008). (Pubitemid 351563997)
139. Sandborn, W. J., Feagan, B. G., Stoinov, S: Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 357: 228-38 (2007). (Pubitemid 47080387)
140. Kaushik, V. V., Moots, R. J: CDP-870 (certolizumab) in rheumatoid arthritis. Expert opinion on biological therapy 5: 601-6 (2005). (Pubitemid 40593341)
141. Peppel, K., Poltorak, A., Melhado, I., Jirik, F., Beutler, B: Expression of a TNF inhibitor in transgenic mice. J.Immunol 151(10): 5699-703 (1993).
142. Kolls, J., Peppel, K., Silva, M., Beutler, B: Prolonged and effective blockade of tumor necrosis factor activity through adenovirus-mediated gene transfer. Proc.Natl.Acad.Sci.USA 91: 215-9 (1994). (Pubitemid 24018674)
143. Van den Brande, J. M., Braat, H., van den Brink, G. R., Versteeg, H. H., Bauer, C. A., Hoedemaeker, I., van Montfrans, C., Hommes, D. W., Peppelenbosch, M. P., van Deventer, S. J: Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology 124 (7): 1774-85 (2003). (Pubitemid 36666774)
144. Choy, E. H., and Panayi, G. S: Cytokine pathways and joint inflammation in rheumatoid arthritis. The New England Journal of Medicine 344: 907-16 (2001). (Pubitemid 32224400)
145. Sole, K: Pegsunercept is a safe and efficacious treatment for rheumatoid arthritis Nature clinical practice rheumatology 2: 121-121 (2006).
146. Furst, D., Fleischmann, R., Kopp, E., Schiff, M., Edwards, C. 3rd., Solinger, A., Macri, M: A phase 2 dosefinding study of PEGylated recombinant methionyl human soluble tumor necrosis factor type I in patients with rheumatoid arthritis. The Journal of rheumatology 32: 2303-2310 (2005). (Pubitemid 41780638)
147. Deree, J., Martins, J. O., Melbostad, H., Loomis, W. H., Coimbra, R: Insights into the regulation of TNF-α production in human mononuclear cells: the effects of nonspecific phosphodiesterase inhibition. Clinics (Sao Paulo) 63: 321-8 (2008).
148. Marqes, L. J., Zheng, L., Poulakis, N., Guzman, J., Costabel, U: Pentoxifylline inhibits TNF-α production from human alveolar macrophages. Am. J. Respir. Crit. Care Med. 159: 508-11 (1999). (Pubitemid 29084873)
149. Kast, R. E., Altschuler, E. L: Anti-apoptosis function of TNF-α in chronic lymphocytic leukemia: lessons from Crohn's disease and the therapeutic potential of bupropion to lower TNF-α. Arch Immunol Ther Exp (Warsz) 53:143-7 (2005). (Pubitemid 41057864)
150. Brustolim, D., Ribeiro-dos-Santos, R., Kast, R. E., Altschuler, E. L., Soares, M. B: A new chapter opens in anti-inflammatory treatments: the antidepressant bupropion lowers production of tumor necrosis factor-alpha; and interferon-gamma in mice. Int. Immunopharmacol 6: 903-7 (2006).
151. Kane, S., Altschuler, E. L., Kast, R. E: Crohn's disease remission on bupropion. Gastroenterology125: 1290 (2003).
152. Kast, R. E., Altschuler, E. L: Remission of Crohn's disease on bupropion. Gastroenterology 121: 1260-1 (2001).
153. Misseri, R., Meldrum, D. R., Dinarello, C. A., Dagher, P., Hile, K. L., Rink, R. C., Meldrum, K, K: TNF-α mediates obstruction-induced renal tubular cell apoptosis and proapoptotic signaling. Am J Physiol Renal Physiol 288: F406-11 (2005).
154. Nomura, T., Abe, Y., Kamada, H., Shibata, H., Kayamuro, H., Inoue, M., Kawara, T., Arita, S., Furuya, T., Yamashita, T., Nagano, K., Yoshikawa, T., Yoshioka, Y., Mukai, Y., Nakagawa, S., Taniai, M., Ohta, T., Serada, S., Naka, T., Tsunoda, S., Tsutsumi, Y: Therapeutic effect of PEGylated TNFR1-selective antagonistic mutant TNF in experimental autoimmune encephalomyelitis mice. J Control Release.149: 8-14 (2011).
155. Shibata, H., Yoshioka, Y., Abe, Y., Ohkawa, A., Nomura, T., Minowa, K., Mukai, Y., Nakagawa, S., Taniai, M., Ohta, T., Kamada, H., Tsunoda, S., Tsutsumi, Y: The treatment of established murine collagen-induced arthritis with a TNFR1-selective antagonistic mutant TNF. Biomaterials 30: 6638-47 (2009).
156. Granado, M., Priego, T., Martín, A. I., Vara, E., López-Calderón, A., Angeles Villanúa, M: Anti-tumor necrosis factor agent PEG-sTNFRI improves the growth hormone/insulin-like growth factor-I system in adjuvantinduced arthritic rats. Eur J Pharmacol. 536: 204-10 (2006).
157. Tartaglia, L. A., Ayres, T. M., Wong, G. H., Goeddel, D. V: A novel domain within the 55 kd TNF receptor signals cell death. Cell 74: 845-853 (1993). (Pubitemid 23270604)
158. Hsu, H., Xiong, J., Goeddel, D. V: The TNF receptor 1-associated protein TRADD signals cell death and NF-ΚB activation. Cell 81: 495-504 (1995).
159. Gonelli, A., Radillo, O., Drioli, S., Rimondi, E., Secchiero, P., Maria Bonora, G: Pegylated TRAIL retains anti-leukemic cytotoxicity and exhibits improved signal transduction activity with respect to TRAIL. Invest New Drugs. 30(2): 828-32 (2012).
160. Kim, T. H., Jiang, H. H., Park, C. W., Youn, Y. S., Lee, S., Chen, X., Lee, K. C:. PEGylated TNF-related apoptosis-inducing ligand (TRAIL)-loaded sustained release PLGA microspheres for enhanced stability and antitumor activity. J Control Release.150(1): 63-9 (2011).
161. Kim, Y. J., Chae, S. Y., Jin, C. H., Sivasubramanian, M., Son, S., Choi, K. Y., Jo, D. G., Kim, K., Chan Kwon, I., Lee, K. C., Park, J. H: Ionic complex systems based on hyaluronic acid and PEGylated TNF-related apoptosisinducing ligand for treatment of rheumatoid arthritis. Biomaterials 31: 9057-64 (2010).
162. Babu, S. K., Puddicombe, S. M., Arshad, H. H., Wilson, S. J., Ward, J., Gozzard, N., Higgs, G., Holgate, S. T., Davies, D. E: Tumor necrosis factor alpha; (TNF-α) autoregulates its expression and induces adhesion molecule expression in asthma. Clin Immunol 140:18-25 (2011).
163. Chakraborty, C., Agoramoorthy, G:Comparative bioinformatic analysis of the conserved domains, amino acid residues, and binding grooves of tumor necrosis factor. Med Glas (Zenica) 11(1):1-6(2014).
164. Klein, R. Q., Spivack, J., Choate, K. A: Psoriatic skin lesions induced by certolizumab pegol. Arch Dermatol 146: 1055-6 (2010).